HC010 / HC Biopharma - LARVOL DELTA

First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4 Trispecific Antibody: Preliminary Results (IASLC-WCLC 2026) - P1 | "Conclusions : HC010 demonstrates a manageable safety profile and promising early efficacy signals in multiple solid tumors, especially among immunotherapy-resistant pts. These findings support further exploration of monotherapy and combination therapy."

First-in-human • P1 data • Trispecific • Endocrine Disorders • Hepatocellular Cancer • Kidney Cancer • Lung Cancer • Mesothelioma • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CTLA4 • PD-1

PT2.02. Metastatic NSCLC – Immunotherapy (IASLC-WCLC 2026) - "Additional presentations highlight innovative combination and next-generation approaches, including the PD-1/VEGF/CTLA-4 trispecific antibody HC010, tislelizumab plus SYS6010, the LIBRA platform study, the ROSETTA Lung-202 phase 3 trial of pumitamig versus pembrolizumab, and the ResQ1010 and ResQ201A trials evaluating nogapendekin alfa inbakicept and NAI-based regimens. Together with a randomized non-inferiority trial of denosumab dosing in bone metastases, these presentations offer a comprehensive view of the evolving therapeutic landscape and unmet needs in metastatic NSCLC immunotherapy."

IO biomarker • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • BRAF • CTLA4 • KEAP1 • KRAS • PD-1 • RET • STK11

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=331 | Recruiting | Sponsor: HC Biopharma Inc.

New P1 trial • Oncology • Solid Tumor

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (clinicaltrials.gov) - P1 | N=328 | Recruiting | Sponsor: HC Biopharma Inc.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: HC Biopharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: HC Biopharma Inc.

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: HC Biopharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor • PD-L1

A Phase I Open-label, Multi-center, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=122 | Not yet recruiting | Sponsor: HC Biopharma Inc.

Metastases • New P1 trial • Oncology • Solid Tumor • PD-L1